(Reuters) - The filing triggers a milestone payment of about 24 million Swiss francs from Johnson & Johnson, with which Basilea is developing Ceftobiprole.
Basilea shares were 2.6 percent higher at 279.00 francs by 0736 GMT.
Read more at Reuters.com Hot Stocks News
Basilea shares were 2.6 percent higher at 279.00 francs by 0736 GMT.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment